Aims: The orexigenic peptide ghrelin may enhance the incentive value of food-, drug-and alcoholrelated rewards. Consistent with preclinical findings, human studies indicate a role of ghrelin in alcohol use disorders (AUD). In the present study an a priori hypothesis-driven analysis was conducted to investigate whether a Leu72Met missense polymorphism (rs696217) in the prepro-ghrelin gene (GHRL), is associated with AUD, alcohol consumption and subjective responses to alcohol. Method: Association analysis was performed using the National Institute on Alcohol Abuse and Alcoholism (NIAAA) clinical sample, comprising AUD individuals and controls (N = 1127). Then, a post-hoc analysis using data from a human laboratory study of intravenous alcohol selfadministration (IV-ASA, N = 144) was performed to investigate the association of this SNP with subjective responses following a fixed dose of alcohol (priming phase) and alcohol selfadministration (ad libitum phase). Results: The case-control study revealed a trend association (N = 1127, OR = 0.665, CI = 0.44-1.01, P = 0.056) between AUD diagnosis and Leu72Met. In AUD subjects, the SNP was associated with significantly lower average drinks per day (n = 567, β = −2.49, 95% CI = −4.34 to −0.64, P = 0.008) and significantly fewer heavy drinking days (n = 567, β = −12.00, 95% CI = −19.10 to −4.89, P < 0.001). The IV-ASA study further revealed that 72Met carriers had greater subjective responses to alcohol (P < 0.05) when compared to Leu72Leu both at priming and during ad lib selfadministration.
INTRODUCTION
Ghrelin is an orexigenic hormone that not only stimulates food intake (Kojima and Kangawa, 2005) but has also been implicated in reward processes leading to alcohol consumption (Addolorato et al., 2006; Jerlhag et al., 2009; Leggio et al., 2012 Leggio et al., , 2014 Suchankova et al., 2013; Gomez et al., 2015; Stevenson et al., 2016) . Located on chromosome 3, the prepro-ghrelin gene (GHRL) has several single nucleotide polymorphisms (SNP); one has been frequently reported in the literature -the Leu72Met (rs696217). This SNP results in an amino acid substitution (leucine to methionine) at residue 72 which is outside the mature ghrelin product of 28 amino acids. Although its function is yet to be established, this polymorphism has been associated with several medical and psychiatric conditions, including diabetes (Liao et al., 2013) , development of obesity (Miraglia del Giudice et al., 2004) and depression (Nakashima et al., 2008) . However, its potential involvement in alcohol use disorders (AUD) is less clear. The possible association of this polymorphism to alcohol-related phenotypes has been investigated previously (Landgren et al., 2008 (Landgren et al., , 2010 (Landgren et al., , 2011a (Landgren et al., , 2011b (Landgren et al., , 2012 but the only positive findings are for a haplotype carrying the 72Leu allele which is associated with increased risk of both reported paternal alcohol dependence as well as withdrawal in severely alcohol dependent women (Landgren et al., 2010) . On the basis of these results, we hypothesize that the 72Leu allele is associated with increased risk of AUD, increased alcohol consumption and altered subjective response to alcohol. This was tested in a relatively large case-control sample and in a human experimental study with social drinkers who underwent an intravenous alcohol self-administration (IV-ASA) procedure.
METHODS AND MATERIALS

Subjects and study procedure
Participants in the case-control study were a subset (N = 1127) of a larger sample (N = 1325) recruited at the NIH Clinical Center in Bethesda, MD, USA, under NIH Institutional Review Board (IRB)-approved screening and evaluation protocols (protocol numbers 98-AA-0009 and 05-AA-0121) ( Table 1 ). All participants provided written informed consent. Cases comprised individuals that had either past or current AUD (n = 816). Controls had no past or current alcohol and/or substance use disorder (n = 311). AUD was diagnosed based on criteria for alcohol abuse and dependence using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID) (First et al., 2002) . Lifetime psychotic disorders, but not other psychiatric comorbidity, were exclusionary. To reduce potential confounds from population stratification, the analysis was limited to the two major self-reported ancestries included in the sample, i.e. Caucasian and African-American, thus excluding subjects of mixed, Asian or unknown descent (n = 130). Control subjects that had a past or current substance use disorder (other than nicotine) were also excluded (n = 14). Average drinks per day and number of heavy drinking days in the AUD group (i.e. more than three or four alcohol drinks per day for women and men, respectively) were estimated for the past 90 days using the Timeline Followback (TLFB; see Table 4 for means) (Sobell et al., 2003) . The IV-ASA study comprised male and female 21-44 year-old non-dependent drinkers (N = 144) who were recruited for an NIH IRB-approved human laboratory study (protocol number 08-AA-0178) ( Table 2 ). All participants provided written informed consent.
The IV-ASA procedure, in which participants self-administer IV alcohol upon pressing a button, has the advantage over oral alcohol exposure to provide precision in terms of breath alcohol concentration (BrAC) exposure, and by assessing self-administration behavior driven primarily by the pharmacological effects of alcohol (Zimmermann et al., 2013) . The IV-ASA consisted of two phases, a priming phase and a self-administration phase ('open-bar' (Stangl et al., 2016) ). During the priming phase (25 min) participants were prompted to push the button to receive four small standardized alcohol infusions resulting in a BrAC level of~30 mg% at 10 min for all participants. During the self-administration phase, the participants were free to press the button any time they wished to receive the standardized IV alcohol infusion. The infusion rates were determined using the subject's age, height, weight and gender in a physiologically-based pharmacokinetic model (Ramchandani et al., 1999) and implemented using the Computerized Alcohol Infusion System (Zimmermann et al., 2013) . Each button press resulted in a 7.5 mg% increase in BrAC at a fixed rate of 3 mg% per minute for a fixed duration of 2.5 min followed by a 1 mg% decrease per minute until the next button press. The button was inactivated (with the participant's knowledge) if the next push passed the pre-set upper limit for BrAC exposure (100 mg%). An Alcotest 7410 handheld breathalyzer (Drager Safety Diagnostics Inc., TX, USA) was administered approximately every 15 minutes during the session. Subjects were asked to fill out a modified version of the Drug Effects Questionnaire (DEQ) (Fraser et al., 1961; Gilman et al., 2008) every 10 min during both the priming phase and every 15 minutes during the self-administration phase in order to evaluate subjective responses to alcohol. Specifically, this modified DEQ consisted of five items scored by the subject using a 100 mm visual analog scale: feel drug, like drug, like more drug, feel high and feel intoxicated.
Genotyping
Genotyping was performed at the NIAAA Laboratory of Neurogenetics. Genomic DNA was extracted from whole blood using standard protocols. DNA samples were genotyped using either the Illumina OmniExpress BeadChip or the Illumina HumanOmniExpressExome array (Illumnia Inc., San Diego, CA, USA). The average genotype reproducibility was 0.99994. The Leu72Met SNP located in the GHRL was extracted from this data and analyzed against the parameters of interest. Ancestry scores for each subject were derived using a panel of 2500 ancestry informative markers (AIMs) by comparison against the CEPH diversity panel (Cann et al., 2002) as described earlier (Lovallo et al., 2015) .
Statistical analyses
Case-control study For the case-control study, association between genotype and clinical status were calculated using logistic regression controlling for AIM scores (Europe and Africa), age and gender.
Heavy drinking days in AUD subjects A linear regression was conducted using the AUD subjects only to investigate whether the SNP was associated with average drinks/day and heavy drinking days. Age, gender, BMI and AIM scores were set as covariates. Additionally, these analyses were performed in males and females separately, given the known gender differences in AUD, to confirm the global analysis was unaffected by gender effects.
IV-ASA study Post-hoc analyses of data obtained from a human laboratory study were conducted. Subjective responses to alcohol were assessed using the five DEQ items at 10 and 20 min during the priming phase, and again using the maximum score reported during the selfadministration phase. Measures from the self-administration phase (following the priming phase) were also analyzed including peak BrAC, average BrAC, total alcohol self-administered in grams and number of subjects reaching a BrAC of 80 mg% (corresponding to a binge exposure). All outcomes were analyzed using linear or logistic regression models, controlling for age, BMI, gender and AIM scores. When analyzing the maximum DEQ scores during the selfadministration phase we included total alcohol self-administered as a covariate to account for individual differences in exposure.
All regression residuals were tested for normal distribution. Skewness scores ranged from −0.534 to 1.197, kurtosis scores ranged from −0.968 to 5.152 and Kolmogorov-Smirnov P-values ranged from <0.001 to 0.20. The normality-assumption was thus not met for all residuals, even following various transformation attempts. Nevertheless, parametric tests were used when analyzing the data due to the lack of a suitable correspondent non-parametric test, and because regression methods are robust to non-normality when sample size is relatively large (Lumley et al., 2002) . Statistical analyses were carried out using IBM SPSS statistics for Mac (version 22.0.0.2, IBM Corp., Armonk, NY, USA) and PLINK version 1.9 (Purcell et al., 2007) .
RESULTS
The Leu72Met was successfully genotyped in cases (n Met72Met = 3, n Leu72Met = 88 and n Leu72Leu = 726) and controls (n Met72Met = 3, n Leu72Met = 42 and n Leu72Leu = 266) and there was no significant deviation from Hardy-Weinberg equilibrium neither in the whole sample (P = 0.22) nor when split by self-reported race (Caucasian P = 0.47 and African Americans P = 1). The case-control analysis revealed an association at trend level with rs696217 in which the 72Met allele appears to have a protective role against AUD (Table 3) .
Significantly lower average drinks per day and fewer heavy drinking days were found in AUD subjects carrying the less common 35.7 (± 4.6) 25.9 (± 4.5) 25.6 (± 4.9) Smokers, n (%) 6 (4.2) 4 (2.8) 2 (1.4) 72Met allele (Table 4 ). When the sample was split according to gender, this association remained significant in both women and men (Table 4 ). In the priming phase of the IV-ASA study, Leu72Met heterozygotes (no Met72Met present in this sample) reported significantly higher levels of feel drug and feel high at 10 min compared to 72Leu homozygotes (Table 5) . Similar tendencies were seen at 20 min of the priming phase (Table 5 ). An association with maximum score of feel high during the self-administration phase was also revealed (Table 5) . No significant associations were found with any of the IV-ASA measures recorded during the self-administration phase.
DISCUSSION
The present study reports an association, albeit at a trend level, between AUD and the Leu72Met SNP located in the GHRL. The protective allele, 72Met, was also associated with significantly lower Table 5 . The Leu72Met SNP located in GHRL is associated with subjective effects of alcohol assessed using the Drug Effects Questionnaire during the priming and the self-administration phases of the intravenous alcohol self-administration procedure Maximum self-reported DEQ score during the self-administration phase; P-values obtained by linear regression controlling for gender, ancestry informative marker scores (Europe and Africa), body mass index, age and total intravenous alcohol self-administered. There were no Met72Met carriers in the sample. Table 4 . The Leu72Met SNP located in GHRL is associated with average drinks per day and heavy drinking days assessed in individuals with alcohol use disorder using the Timeline Followback
Average drinks/day All (n = 499/68) 10.9 (7.2) 8.7 ( Obtained by linear regression controlling for gender, ancestry informative marker scores (Europe and Africa), body mass index and age. n reported as number of individuals with the Leu72Leu genotype/Met72Leu + Met72Met genotypes (a dominant model was assumed due to few individuals carrying the Met72Met). average in drinks/day and fewer heavy drinking days in AUD subjects carrying the GHRL 72Met allele. During the priming phase of the human laboratory experiment of social drinkers administering alcohol IV, 72Met carriers reported increased subjective effects (feel drug and feel high) compared to Leu72Leu homozygotes. The association between 72Met and increased feeling of high was also seen when analyzing the maximum score reported during the selfadministration phase. Although preliminary, together these results suggest a potential role of this polymorphism in altering alcoholrelated behaviors and effects, thus warranting future investigations.
It is important to note that we studied social drinkers in the human laboratory study and AUD individuals in the case-control study. Altogether, the associations reported here lead us to hypothesize that the Leu72Leu variant of this SNP may play a role in the development of AUD perhaps by predisposing some people to excessive alcohol use. A low response to alcohol has been shown to predict future higher quantities of alcohol consumed per occasion and alcohol problems (Schuckit et al., 2015) . We thus hypothesize that the lower subjective effects reported by social drinkers with the Leu72Leu genotype in this study may be a predictor of future heavy drinking days and AUD.
The role of ghrelin in alcohol reward has been established in preclinical studies (Jerlhag et al., 2009 ) and exogenous ghrelin administration has been shown to increase alcohol cue-elicited craving in AUD individuals (Leggio et al., 2014) . One could thus expect that genetic variations in this system would affect alcohol-related behaviors, which has been reported in some studies (Landgren et al., 2008 (Landgren et al., , 2010 (Landgren et al., , 2012 Leggio et al., 2012; Suchankova et al., 2016) . Previous work on the Leu72Met polymorphism and AUD has, however, generated mixed results (Leggio et al., 2012; Suchankova et al., 2016) , possibly due to the large differences in sample sizes (i.e., much smaller in Leggio et al., 2012) . In line with our findings the 72Leu allele was present in a haplotype associated with self-reported paternal alcohol dependence as well as withdrawal in severely alcohol dependent women (Landgren et al., 2010) .
The study is faced with some limitations. First, we studied two different groups rather than a single group followed longitudinally, therefore we can only speculate on the potential role of this SNP (rs696217) in the development of excessive drinking in AUD. Second, while this SNP results in a amino acid substitution at residue 72 in the pro-peptide, this amino-acid residue is outside the mature 28-aminoacid ghrelin product and the functional consequences of the substitution is unknown; in that regard, we were not able to test whether genetic variant of this SNP may result in different peripheral ghrelin levels. Third, our data indicate an association but do not establish causality. Finally, due to the exploratory nature of our study we used a liberal method when testing for normality rather than the very stringent Shapiro-Wilk test. On the other hand, this study also has some strengths. First, the case-control study and the sample of the AUD group was relatively large or at least larger compared to previous studies that looked at this SNP. Second, while no genome-wide association study has reported a role of this SNP, and the single SNP approach might be questioned for this reason, our analyses were based on a specific, hypothesis-driven research question stemming from the well documented role of ghrelin in appetitive behaviors. Third, the human laboratory study served as a model, albeit preliminary, for further investigation of this SNP using data from an experiment conducted in a well-controlled setting.
Our study should be regarded as preliminary until confirmed in other samples. For exploratory purposes we did not adjust P-values for multiple testing. However with the total of 22 outcomes investigated here, using Bonferroni correction would require a cutoff P-value of 0.002.
In conclusion, the present study suggests a potential role of the prepro-ghrelin Leu72Met polymorphism in AUD and alcoholrelated behaviors and effects. Future studies are needed to replicate and expand on these preliminary findings.
